Regulation & law · 21/09/2000Updated: 10/17/2026 · 1 min read
National Institutes of Health to Grant Exclusive License for Gaucher Disease Treatment
Summary
The National Institutes of Health is considering granting a worldwide exclusive license to BioPrime, Inc. to practice patents related to Gaucher disease treatment, including U.S. Patent 5,705,153 and U.S. Patent 5,879,680.
Original source language: Federal Register — All DocumentsOpen original release →